Vect-Horus Revenue

Biotechnology Research • Marseille, Provence-Alpes-Côte d'Azur, France • 21-50 Employees

Vect-Horus revenue & valuation

Annual revenue	$4,192,195
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$13,500,000
Total funding	$6,400,000

Key Contacts at Vect-Horus

Cédric Malicet

Oncology Program Director

Stéphane Girard

Team Leader Neurohistology & Ophthalmology Program Director

Guillaume Jacquot

Program Director, Brain & Tissue Targeting Of Oligonucleotides

Company overview

Headquarters	27, Bd Jean Moulin, Faculté de la Timone, MARSEILLE , PACA 13005, FR
Phone number	+33491698781
Website	vect-horus.com
NAICS	541714
SIC	873
Founded	2005
Employees	21-50
Socials

Vect-Horus Email Formats

Vect-Horus uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@vect-horus.com), used 66.7% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@vect-horus.com	66.7%
{first initial}.{last name}	j.doe@vect-horus.com	33.3%

About Vect-Horus

VECT-HORUS, Breaking barriers Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumours. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (first and foremost the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Vect-Horus endorces a mixed business model, based on its proprietary VECTrans® technology, both to make its technology platform available to pharmaceutical and biotechnology company partners and to develop an internal pipeline of products. Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder. Based in Marseille, France, the company has 35 employees, mostly in R&D, and develops academic collaborations with the CNRS, INSERM and CEA as well as industrial partnerships.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Manager

C-Suite

Employees by Department

Vect-Horus has 27 employees across 6 departments.

Departments

Number of employees

Funding Data

Explore Vect-Horus's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2021-01-01	7	$6,400,000

Funding Insights

$6,400,000

Total funding amount

$6,400,000

Most recent funding amount

Number of funding rounds

Vect-Horus Tech Stack

Discover the technologies and tools that power Vect-Horus's digital infrastructure, from frameworks to analytics platforms.

reCAPTCHA

Security

jQuery

JavaScript libraries

Nginx

Reverse proxies

PHP

Programming languages

SPIP

CMS

Vimeo

Video players

OVHcloud

Hosting

Bootstrap

UI frameworks

Firebase

Databases

RSS

Miscellaneous

Google Font API

Font scripts

Microsoft 365

Frequently asked questions

Vect-Horus is located in Marseille, Provence-Alpes-Côte d'Azur, FR.

You can reach Vect-Horus at +33491698781.

Vect-Horus generates an estimated annual revenue of $4,192,195. This revenue figure reflects the company's market position and business performance in its industry.

Vect-Horus has an estimated valuation of $13,500,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Vect-Horus was founded in 2005, making it 21 years old. The company has established itself as a significant player in its industry over this time.

Vect-Horus has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Vect-Horus has raised a total of $6,400,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.